|
1
|
Hochhaus A, Saglio G, Hughes TP, Larson
RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G,
Dorlhiac-Llacer PE, Clark RE, et al: Long-term benefits and risks
of frontline nilotinib vs imatinib for chronic myeloid leukemia in
chronic phase: 5-year update of the randomized ENESTnd trial.
Leukemia. 30:1044–1054. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hochhaus A, Rosti G, Cross NC, Steegmann
JL, le Coutre P, Ossenkoppele G, Petrov L, Masszi T, Hellmann A,
Griskevicius L, et al: Frontline nilotinib in patients with chronic
myeloid leukemia in chronic phase: Results from the European
ENEST1st study. Leukemia. 30:57–64. 2016. View Article : Google Scholar :
|
|
3
|
Breccia M, Stagno F, Luciano L, Abruzzese
E, Annunziata M, D'Adda M, Maggi A, Sgherza N, Russo-Rossi A,
Pregno P, et al: Dasatinib first-line: Multicentric Italian
experience outside clinical trials. Leuk Res. 40:24–29. 2016.
View Article : Google Scholar
|
|
4
|
Hughes TP and Ross DM: Moving
treatment-free remission into mainstream clinical practice in CML.
Blood. 128:17–23. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vaidya S, Vundinti BR, Shanmukhaiah C,
Chakrabarti P and Ghosh K: Evolution of BCR/ABL gene mutation in
CML is time dependent and dependent on the pressure exerted by
tyrosine kinase inhibitor. PLoS One. 10:e01148282015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Parker WT, Yeung DT, Yeoman AL, Altamura
HK, Jamison BA, Field CR, Hodgson JG, Lustgarten S, Rivera VM,
Hughes TP, et al: The impact of multiple low-level BCR-ABL1
mutations on response to ponatinib. Blood. 127:1870–1880. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Soverini S, Hochhaus A, Nicolini FE,
Gruber F, Lange T, Saglio G, Pane F, Müller MC, Ernst T, Rosti G,
et al: BCR-ABL kinase domain mutation analysis in chronic myeloid
leukemia patients treated with tyrosine kinase inhibitors:
Recommendations from an expert panel on behalf of European
LeukemiaNet. Blood. 118:1208–1215. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Turhan AG: STAT5 as a CML target: STATinib
therapies? Blood. 117:3252–3253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Warsch W, Grundschober E and Sexl V:
Adding a new facet to STAT5 in CML: Multitasking for leukemic
cells. Cell Cycle. 12:1813–1814. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Warsch W, Kollmann K, Eckelhart E, Fajmann
S, Cerny-Reiterer S, Hölbl A, Gleixner KV, Dworzak M, Mayerhofer M,
Hoermann G, et al: High STAT5 levels mediate imatinib resistance
and indicate disease progression in chronic myeloid leukemia.
Blood. 117:3409–3420. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Walz C, Ahmed W, Lazarides K, Betancur M,
Patel N, Hennighausen L, Zaleskas VM and Van Etten RA: Essential
role for Stat5a/b in myeloproliferative neoplasms induced by
BCR-ABL1 and JAK2(V617F) in mice. Blood. 119:3550–3560. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carter BZ, Mak PY, Mak DH, Ruvolo VR,
Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE,
Konopleva M, et al: Synergistic effects of p53 activation via MDM2
inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in
CD34+ proliferating and quiescent chronic myeloid
leukemia blast crisis cells. Oncotarget. 6:30487–30499. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hughes T, Deininger M, Hochhaus A,
Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC,
Druker BJ, et al: Monitoring CML patients responding to treatment
with tyrosine kinase inhibitors: Review and recommendations for
harmonizing current methodology for detecting BCR-ABL transcripts
and kinase domain mutations and for expressing results. Blood.
108:28–37. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baccarani M, Deininger MW, Rosti G,
Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes
JE, Guilhot F, et al: European LeukemiaNet recommendations for the
management of chronic myeloid leukemia: 2013. Blood. 122:872–884.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dong HJ, Zhou LT, Zhu DX, Wang DM, Fang C,
Zhu HY, Zhuang Y, Miao KR, Xu W and Li JY: The prognostic
significance of TP53 mutations in Chinese patients with chronic
lymphocytic leukemia is independent of del(17p13). Ann Hematol.
90:709–717. 2011. View Article : Google Scholar
|
|
16
|
Lan X, Zhao C, Chen X, Zhang P, Zang D, Wu
J, Chen J, Long H, Yang L, Huang H, et al: Nickel pyrithione
induces apoptosis in chronic myeloid leukemia cells resistant to
imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent
mechanisms. J Hematol Oncol. 9:1292016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shi X, Chen X, Li X, Lan X, Zhao C, Liu S,
Huang H, Liu N, Liao S, Song W, et al: Gambogic acid induces
apoptosis in imatinib-resistant chronic myeloid leukemia cells via
inducing proteasome inhibition and caspase-dependent Bcr-Abl
downregulation. Clin Cancer Res. 20:151–163. 2014. View Article : Google Scholar :
|
|
18
|
Wu L, Chen X, Huang L, Tian J, Ke F, Xu J,
Chen Y and Zheng M: A Novobiocin derivative, XN4, inhibits the
proliferation of chronic myeloid leukemia cells by inducing
oxidative DNA damage. PLoS One. 10:e01233142015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ismail IH, Wadhra TI and Hammarsten O: An
optimized method for detecting gamma-H2AX in blood cells reveals a
significant interindividual variation in the gamma-H2AX response
among humans. Nucleic Acids Res. 35:e362007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ren G, Luo W, Sun W, Niu Y, Ma DL, Leung
CH, Wang Y, Lu JJ and Chen X: Psoralidin induced reactive oxygen
species (ROS)-dependent DNA damage and protective autophagy
mediated by NOX4 in breast cancer cells. Phytomedicine. 23:939–947.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maillet A and Pervaiz S: Redox regulation
of p53, redox effectors regulated by p53: a subtle balance.
Antioxid Redox Signal. 16:1285–1294. 2012. View Article : Google Scholar
|
|
22
|
Banerjee K, Ganguly A, Chakraborty P,
Sarkar A, Singh S, Chatterjee M, Bhattacharya S and Choudhuri SK:
ROS and RNS induced apoptosis through p53 and iNOS mediated pathway
by a dibasic hydroxamic acid molecule in leukemia cells. Eur J
Pharm Sci. 52:146–164. 2014. View Article : Google Scholar
|
|
23
|
Chomel JC, Bonnet ML, Sorel N, Bertrand A,
Meunier MC, Fichelson S, Melkus M, Bennaceur-Griscelli A, Guilhot F
and Turhan AG: Leukemic stem cell persistence in chronic myeloid
leukemia patients with sustained undetectable molecular residual
disease. Blood. 118:3657–3660. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Branford S, Rudzki Z, Walsh S, Parkinson
I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour JF, Arthur C, et
al: Detection of BCR-ABL mutations in patients with CML treated
with imatinib is virtually always accompanied by clinical
resistance, and mutations in the ATP phosphate-binding loop
(P-loop) are associated with a poor prognosis. Blood. 102:276–283.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Raja T: Optimizing second-line therapy for
chronic myeloid leukemia. Indian J Cancer. 49:46–56. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Y, Cai D, Brendel C, Barett C, Erben
P, Manley PW, Hochhaus A, Neubauer A and Burchert A: Adaptive
secretion of granulocyte-macrophage colony-stimulating factor
(GM-CSF) mediates imatinib and nilotinib resistance in
BCR/ABL+ progenitors via JAK-2/STAT-5 pathway
activation. Blood. 109:2147–2155. 2007. View Article : Google Scholar
|
|
27
|
Hoelbl A, Schuster C, Kovacic B, Zhu B,
Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G, et
al: Stat5 is indispensable for the maintenance of bcr/abl-positive
leukaemia. EMBO Mol Med. 2:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hoelbl A, Kovacic B, Kerenyi MA, Simma O,
Warsch W, Cui Y, Beug H, Hennighausen L, Moriggl R and Sexl V:
Clarifying the role of Stat5 in lymphoid development and
Abelson-induced transformation. Blood. 107:4898–4906. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang WW, Cortes JE, Yao H, Zhang L, Reddy
NG, Jabbour E, Kantarjian HM and Jones D: Predictors of primary
imatinib resistance in chronic myelogenous leukemia are distinct
from those in secondary imatinib resistance. J Clin Oncol.
27:3642–3649. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mallette FA, Moiseeva O, Calabrese V, Mao
B, Gaumont-Leclerc MF and Ferbeyre G: Transcriptome analysis and
tumor suppressor requirements of STAT5-induced senescence. Ann NY
Acad Sci. 1197:142–151. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gorrini C, Harris IS and Mak TW:
Modulation of oxidative stress as an anticancer strategy. Nat Rev
Drug Discov. 12:931–947. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Reczek CR and Chandel NS: ROS-dependent
signal transduction. Curr Opin Cell Biol. 33:8–13. 2015. View Article : Google Scholar :
|
|
33
|
Brem R, Li F, Montaner B, Reelfs O and
Karran P: DNA breakage and cell cycle checkpoint abrogation induced
by a therapeutic thiopurine and UVA radiation. Oncogene.
29:3953–3963. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gu B and Zhu WG: Surf the
post-translational modification network of p53 regulation. Int J
Biol Sci. 8:672–684. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bejar R, Stevenson K, Abdel-Wahab O,
Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine
RL, Neuberg D, et al: Clinical effect of point mutations in
myelodysplastic syndromes. N Engl J Med. 364:2496–2506. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kulasekararaj AG, Smith AE, Mian SA,
Mohamedali AM, Krishnamurthy P, Lea NC, Gäken J, Pennaneach C,
Ireland R, Czepulkowski B, et al: TP53 mutations in myelodysplastic
syndrome are strongly correlated with aberrations of chromosome 5,
and correlate with adverse prognosis. Br J Haematol. 160:660–672.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Perrotti D, Jamieson C, Goldman J and
Skorski T: Chronic myeloid leukemia: Mechanisms of blastic
transformation. J Clin Invest. 120:2254–2264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Woo SM, Choi YK, Kim AJ, Cho SG and Ko SG:
p53 causes butein mediated apoptosis of chronic myeloid leukemia
cells. Mol Med Rep. 13:1091–1096. 2016. View Article : Google Scholar
|
|
39
|
Haupt Y, Maya R, Kazaz A and Oren M: Mdm2
promotes the rapid degradation of p53. Nature. 387:296–299. 1997.
View Article : Google Scholar : PubMed/NCBI
|
